Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adefovir Dipivoxil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 3/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | POLA1 | P09884 | 1/20 | 1.00 |
| ▸ | POLG | P54098 | 1/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.62 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.46 |
| ▸ | NSD3 | Q9BZ95 | 2/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adefovir Dipivoxil SCHEMBL29372789 | 1.00 | FAP (1.00) | FAPSLC22A6ABCB11POLA1POLG | |
| Adefovir Dipivoxil SCHEMBL5845498 | 1.00 | FAP (1.00) | FAPSLC22A6ABCB11POLA1POLG | |
| Adefovir Dipivoxil SCHEMBL3719079 | 0.99 | FAP (0.98) | FAPSLC22A6ABCB11POLA1POLG | |
| Adefovir Dipivoxil SCHEMBL3646944 | 0.99 | FAP (0.98) | FAPSLC22A6ABCB11POLA1POLG | |
| SCHEMBL12391572 | 0.96 | FAP (0.93) | FAPSLC22A6ABCB11POLA1POLG | |
| Adefovir Dipivoxil SCHEMBL457147 | 0.96 | FAP (0.93) | FAPSLC22A6ABCB11POLA1POLG | |
| Adefovir Dipivoxil SCHEMBL3745803 | 0.96 | FAP (0.93) | FAPSLC22A6ABCB11POLA1POLG | |
| Adefovir Dipivoxil SCHEMBL2787331 | 0.94 | FAP (0.88) | FAPSLC22A6ABCB11POLA1POLG | |
| SCHEMBL13239804 | 0.93 | FAP (0.87) | FAPSLC22A6ABCB11POLA1POLG | |
| SCHEMBL12391569 | 0.91 | SLC22A6 (0.84) | FAPSLC22A6ABCB11POLA1POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 31026 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| WO-2026107341-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | Vir Biotechnology, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| CN-122005580-A | Application of adefovir in preparing medicine for preventing and treating atherosclerosis | 济宁市第一人民医院(济宁市医学科学研究院) | 2026-05-12 | — | — | CN | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4444311-B1 | GINSENOSIDES FOR TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTIONS | MENDEL UNIV IN BRNO (CZ) | 2026-05-06 | — | — | EP | claimed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| WO-1999066936-A1 | USE OF 3'-AZIDO-2',3'-DIDEOXYURIDINE IN COMBINATION WITH FURTHER ANTI-HIV DRUGS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HIV | EMORY UNIVERSITY (US) | 1999-12-29 | — | — | WO | claimed |
| WO-1999064048-A1 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| WO-1999055845-A1 | CELLULAR AND ANIMAL MODELS FOR DISEASES ASSOCIATED WITH ALTERED MITOCHONDRIAL FUNCTION | MITOKOR (US) | 1999-11-04 | — | — | WO | claimed |
| WO-1999051613-A1 | PRODRUGS OF PHOSPHOROUS-CONTAINING PHARMACEUTICALS | MEDIVIR AB (SE) | 1999-10-14 | — | — | WO | claimed |
| WO-1999048526-A1 | METHOD OF RENDERING A HUMAN IMMUNODEFICIENCY VIRUS POPULATION REPLICATION INCOMPETENT $i(IN VIVO) | LORI FRANCO (US) | 1999-09-30 | — | — | WO | claimed |
| WO-1999048504-A1 | COMPOSITIONS FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS USING HYDROXYUREA AND A REVERSE TRANSCRIPTASE INHIBITOR | LISZIEWICZ JULIANNA (US) | 1999-09-30 | — | — | WO | claimed |
| WO-1999045025-A1 | ACYLATED BETULIN AND DIHYDROBETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1999-09-10 | — | — | WO | claimed |
| WO-1999041268-A1 | NUCLEOSIDES | MEDIVIR AB (SE) | 1999-08-19 | — | — | WO | claimed |
| WO-1999036406-A1 | ANTIVIRALS | MEDIVIR AB (SE) | 1999-07-22 | — | — | WO | claimed |
| WO-1999004774-A2 | NUCLEOTIDE ANALOG COMPOSITIONS | GILEAD SCIENCES, INC. (US) | 1999-02-04 | — | — | WO | claimed |